SLNO

Over the past six months, Soleno Therapeutics' stock has experienced significant events. Key events impacting the stock include the FDA approval and commercial launch of VYKAT XR, leading to rapid profitability with $66.0 million in Q3 2025 revenue and $91.7 million in Q4 2025 revenue. Soleno achieved profitability with a positive net income of $20.9 million for the full year 2025 and generated $48.7 million of cash flow from operating activities in the fourth quarter of 2025. In November 2025, the company announced and invested $100 million in an accelerated share repurchase program. On April 5, 2026, Neurocrine Biosciences agreed to acquire Soleno Therapeutics through a cash tender offer of $53.00 per share, to be followed by a merger. A securities fraud lawsuit was filed against Soleno Therapeutics, Inc., alleging that the company downplayed or concealed safety concerns related to DCCR, including issues with excess fluid retention in clinical trial participants.